دورية أكاديمية
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
| العنوان: | Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial |
|---|---|
| المؤلفون: | Ginzac, AngelineAff1, Aff2, Aff3, IDs1054902407285y_cor1, Molnar, IoanaAff1, Aff2, Aff3, Durando, XavierAff1, Aff2, Aff3, Aff4, Motte Rouge, Thibault De La, Petit, Thierry, D’hondt, Véronique, Campone, Mario, Bonichon-Lamichhane, Nathalie, Venat Bouvet, Laurence, Levy, Christelle, Augereau, Paule, Pistilli, Barbara, Arsene, Olivier, Jouannaud, Christelle, Nguyen, Suzanne, Cayre, Anne, Tixier, Lucie, Mahier Ait Oukhatar, Céline, Nabholtz, Jean-Marc, Penault-Llorca, FrédériqueAff1, Aff16, Mouret-Reynier, Marie-Ange |
| المصدر: | Breast Cancer Research and Treatment. 205(2):267-279 |
| قاعدة البيانات: | Springer Nature Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 01676806 15737217 |
|---|---|
| DOI: | 10.1007/s10549-024-07285-y |